Cost-effectiveness and impact of five different point of care strategies to preserve last line treatment for gonorrhoea
Examining the acceptability of offering STI screening in higher educational settings
Modelling the choice of high-risk human papillomavirus (HR-HPV) assay in the English cervical screening programme
Cost analysis of near patient chlamydia and gonorrhoea screening and treatment in further education/technical colleges
Cluster-randomised feasibility trial of a chlamydia test and treat (TnT) service in further education colleges
Modelling cost-effectiveness of multipathogen POC tests for sexually transmitted infections
Three simple tests could save the NHS nearly £6.9 billion
Test n Treat – rapid STI testing and treatment in colleges: study protocol
Estimating the true costs of splitting HIV antiretroviral drugs
There is a temptation to switch to cheaper generic antiretroviral drugs compared to fixed-dose combination therapy for HIV patients in the interests of cost savings. However, in our analysis we found that there were no costs saved when including all patient care including drugs, additional clinic visits and monitoring. We also found that switching may cause confusion for some patients, risking loss of adherence. This evidence can help commissioners make better policy decisions about drug provision.
Increased efficiency and improved treatment for stable HIV patients in England
Collaborators at St Georges Hospital wanted to understand the impact of changing service provision for stable HIV patients, as no evidence existed on what was best for clinics. We built a tool in Excel, and results indicated that 6-monthly appointments and 3-monthly home delivery of drugs is the cheapest option and could yield £2000 savings per patient, translating to an annual cost reduction of ~£8 million for the estimated 4000 eligible patients not currently on home delivery in England in 2012.